Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Hemodialysis on Cutaneous Manifestations of Chronic Kidney Disease
8
Mins
April 2024
Chronic kidney disease (CKD) is a non-communicable disease that currently widely affects around 850 million people. Nowadays…
Read more
3
Mins
16th May 2023
Cutaneous Squamous Cell Carcinoma of the Hand Presenting as Clinical Perineural Invasion
Cutaneous squamous cell carcinoma (SCC) contributes to 20% of non-melanoma skin cancers and early diagnosis is vital to reducing…
11
Mins
12th April 2023
IL-17 and -23 Inhibitors for the Treatment of Psoriasis
Psoriasis is a chronic inflammatory skin disorder affecting approximately 60 million people worldwide. The condition presents with rapid hyperproliferation and dysregulated differentiation of epidermal keratinocytes, manifesting clinically as salmon pink plaques with overlying silvery-white scale.
25th November 2022
Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study
As part of the 31st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7th–10th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines.
11
Mins
14th November 2022
An Overview of the EORTC-CLTG 2022 Congress
This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes.
6
Mins
20th October 2022
Photoprotection and the Science Behind Skin Healing
Sun exposure can lead to tanning, but also to skin damage due to the actions of ultraviolet A and B, visible light, and infrared radiation. One result of sun exposure is field cancerisation (FC), the precursor to actinic keratosis (AK), which in turn is a risk factor for, most notably, squamous cell carcinoma.
6
Mins
20th October 2022
Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study
Chronic spontaneous urticaria (CSU) is characterised by the spontaneous occurrence of wheals (hives) and/or angioedema for ≥6 weeks.1 CSU can persist for several years and is associated with severe pruritus. Skin mast cell activation in CSU occurs via Type I autoallergy driven by IgE to autoallergens, and a Type IIb autoimmune response due to mast cell-targeted autoantibodies against IgE or high-affinity IgE receptor.
5
Mins
20th October 2022
Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials
The primary endpoint analyses from the SUNSHINE and SUNRISE Phase III trials of secukinumab in moderate-to-severe hidradenitis suppurativa (HS) were featured in an oral presentation as part of the late-breaking news session at the 31st annual European Academy of Dermatology and Venereology (EADV) congress. Known collectively as the SUNNY trials, the SUNSHINE and SUNRISE studies represent the largest Phase III trials conducted in HS to date.
5
Mins
4th July 2022
Editor's Pick: Pemphigus Vulgaris and Pemphigus Foliaceus: A Single-Centre Comparative Study in Rabat, Morocco
Pemphigus is a group of rare autoimmune blistering diseases affecting the skin and mucous membranes. Pemphigus foliaceus (PF)…
Loading posts...
« Previous
1
2
3
4
5
6
…
25
Next »